Literature DB >> 32277177

Genotype-phenotype correlations and effect of mutation location in Japanese CADASIL patients.

Mao Mukai1, Ikuko Mizuta1, Akiko Watanabe-Hosomi1, Takashi Koizumi1, Jun Matsuura1, Ai Hamano1, Hidekazu Tomimoto2, Toshiki Mizuno3.   

Abstract

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a hereditary cerebral small vessel disease caused by NOTCH3, and characterized by recurrent cerebral ischemic events without vascular risk factors, mood disturbance, and dementia. MRI testing shows cerebral white matter hyperintensities, especially in the external capsule and temporal pole. Typical mutations are cysteine-related missense ones located in one of 34 EGF-like repeats (EGFr) in the NOTCH3 receptor. To identify genotype-phenotype correlations, 179 Japanese CADASIL probands were recruited. Of the 68 mutations identified, p.Cys388Arg, p.Cys435Phe, p.Gly481Cys, p.Cys743Tyr, and p.Cys1009Phe were novel ones. The genotype-phenotype correlation was analyzed based on the three most common mutations: p.Arg75Pro, p.Arg141Cys, and p.Arg182Cys. p.Arg141Cys showed typical CADASIL phenotypes, whereas p.Arg75Pro showed mild and atypical phenotypes, a low frequency of stroke/TIA, high frequency of hypertension, and low frequency of temporal pole lesions. p.Arg182Cys showed various initial symptoms other than stroke/TIA. Subsequently, we analyzed the effect of the mutation location on the age at onset of stroke/TIA. We found that mutations in EGFr 1-6 excluding the cysteine-sparing mutation p.Arg75Pro were significantly correlated with a younger age at onset of stroke/TIA compared with those in EGFr 7-34. This was in agreement with a recent European report, suggesting that the effect of the mutation location is a consensus finding in CADASIL worldwide.

Entities:  

Year:  2020        PMID: 32277177     DOI: 10.1038/s10038-020-0751-9

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  6 in total

1.  Mutation spectrum and genotype-phenotype correlations in 157 Korean CADASIL patients: a multicenter study.

Authors:  Ji-You Min; Seo-Jin Park; Eun-Joo Kang; Seung-Yong Hwang; Sung-Hee Han
Journal:  Neurogenetics       Date:  2021-11-06       Impact factor: 2.660

2.  Detecting Key Functional Components Group and Speculating the Potential Mechanism of Xiao-Xu-Ming Decoction in Treating Stroke.

Authors:  Yu-Peng Chen; Ke-Xin Wang; Jie-Qi Cai; Yi Li; Hai-Lang Yu; Qi Wu; Wei Meng; Han-Duo Wang; Chuan-Hui Yin; Jie Wu; Mian-Bo Huang; Rong Li; Dao-Gang Guan
Journal:  Front Cell Dev Biol       Date:  2022-05-12

3.  Prevalence and Atypical Clinical Characteristics of NOTCH3 Mutations Among Patients Admitted for Acute Lacunar Infarctions.

Authors:  Takashi Okada; Kazuo Washida; Kenichi Irie; Satoshi Saito; Michio Noguchi; Tsutomu Tomita; Masatoshi Koga; Kazunori Toyoda; Shuhei Okazaki; Takashi Koizumi; Ikuko Mizuta; Toshiki Mizuno; Masafumi Ihara
Journal:  Front Aging Neurosci       Date:  2020-05-14       Impact factor: 5.750

4.  Association of NOTCH3 Variant Position With Stroke Onset and Other Clinical Features Among Patients With CADASIL.

Authors:  Bernard P H Cho; Amy A Jolly; Stefania Nannoni; Daniel Tozer; Steven Bell; Hugh S Markus
Journal:  Neurology       Date:  2022-05-31       Impact factor: 11.800

5.  Effect of NOTCH3 EGFr Group, Sex, and Cardiovascular Risk Factors on CADASIL Clinical and Neuroimaging Outcomes.

Authors:  Remco J Hack; Minne N Cerfontaine; Gido Gravesteijn; Stephan Tap; Anne Hafkemeijer; Jeroen van der Grond; Marie-Noëlle Witjes-Ané; Frank Baas; Julie W Rutten; Saskia A J Lesnik Oberstein
Journal:  Stroke       Date:  2022-07-13       Impact factor: 10.170

6.  NOTCH3 variant position is associated with NOTCH3 aggregation load in CADASIL vasculature.

Authors:  Gido Gravesteijn; Remco J Hack; Aat A Mulder; Minne N Cerfontaine; Remco van Doorn; Ingrid M Hegeman; Carolina R Jost; Julie W Rutten; Saskia A J Lesnik Oberstein
Journal:  Neuropathol Appl Neurobiol       Date:  2021-07-30       Impact factor: 6.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.